Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRECIZUMAB in Early Septic Shock With Elevated Adrenomedullin (Phase II)
2016-003883-38Phase 2Completed
- Sponsor
- Adrenomed AG
- Start
- Mar 2017
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adrecizumab in septic shock (3 arms), sponsored by Adrenomed AG. Primary endpoint: Mortality. Started Mar 2017; status: completed.
02
Drugs
adrecizumab
03
Conditions
septic shock
Beyond the preview
Go deeper on 2016-003883-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003883-38.